AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00812864
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day
Trial: NCT00252564
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 on Days 1 and 15
Trial: NCT00252564
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
Trial: NCT02888964
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone therapy
Trial: NCT00756171
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times 3 625mg tablets daily
Trial: NCT00133380
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00467597
Drug: Levodopa (delivered intravenously)
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit.
Trial: NCT00634205
Drug: Valproate plus doxorubicin
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
Trial: NCT00868998
Drug: Gemcitabine, docetaxel, and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
Trial: NCT00003209
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003209
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00070941
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
Trial: NCT01710722
Drug: caffeine and ephedrine
RxNorm normalized name: acetanilide / aspirin / caffeine / ephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
Trial: NCT01710722
Drug: caffeine, ephedrine, and leptin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
Trial: NCT01395017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03195387
Drug: MMV390048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
Trial: NCT01782937
Drug: KHK4827
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
Trial: NCT01101932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
Trial: NCT00441961
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate
Trial: NCT03366428
Drug: DS-8201a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
Trial: NCT00494078
Drug: intensive insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive insulin therapy according to an algorithm
Trial: NCT00405262
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
Trial: NCT00405262
Drug: ketorolac + bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
Trial: NCT00532012
Drug: RhuDex®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00785603
Drug: Paroxetin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
Trial: NCT01392807
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Oral tablets, single dose
Trial: NCT01728987
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule looking identical to the cholecalciferol capsule
Trial: NCT00634556
Drug: levodopa solution 2mg/ml for i.v. use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/mL in normal saline
Trial: NCT00634556
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT02051608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Placebo SC injection Q4W.
Trial: NCT01940159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose placebo
Trial: NCT00162656
Drug: half cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00162656
Drug: without COPADM3
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00162656
Drug: mini CYVE, without 3 maintenance courses
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00112437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
Trial: NCT02011828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT00379353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules orally, once a day for 14 days.
Trial: NCT02004691
Drug: placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion
Trial: NCT03060070
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml of 0.25% bupivacaine will be injected in each side of the TAP block
Trial: NCT00893945
Drug: DC/AAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
Trial: NCT00893945
Drug: DC/KLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
Trial: NCT02086838
Drug: low molecular weight iron dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03201276
Drug: Glucosamine Sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients taking glucosamine sulfate 1500mg every day for at least four days.
Trial: NCT00284583
Drug: Injection of Steroid into Foot
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00284583
Drug: Injection of Alcohol into Foot
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03513185
Drug: Deanxit, SSRI or SRNI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
Trial: NCT01189747
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected into bilateral Crow's Feet Line areas on Day 1
Trial: NCT02271035
Drug: Deflux
RxNorm normalized name: Deflux
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
Trial: NCT04330547
Drug: Analgesic administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)
Trial: NCT04330547
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folavit (folic acid, 0.4 mg)
Trial: NCT01665404
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of RO4917523
Trial: NCT01049464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
Trial: NCT04980105
Drug: Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)
RxNorm normalized name: methylprednisolone acetate Injection
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
Trial: NCT01625403
Drug: rhBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of rhBNP 0.01 µg/kg/min
Trial: NCT00899951
Drug: fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00902538
Drug: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
Trial: NCT00902538
Drug: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
Trial: NCT00902538
Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
Trial: NCT02927431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
Trial: NCT02881086
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02881086
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02881086
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02881086
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00902538
Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
Trial: NCT02387762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03465202
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03531827
Drug: CRLX101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
Trial: NCT02865824
Drug: Continue thienopyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
Trial: NCT02865824
Drug: Discontinue thienopyridine
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
Trial: NCT01717040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
Trial: NCT02691676
Drug: Plasmalyte
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
Trial: NCT04264533
Drug: VC
RxNorm normalized name: VCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
Trial: NCT01116011
Drug: AZD7268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, BID
Trial: NCT01116011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, BID
Trial: NCT03234686
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
Trial: NCT02235480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04388358
Drug: Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were treated with mixed formula of Chinese medicine for one month
Trial: NCT01939990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo looks like the study drug but it does not contain active ingredients.
Trial: NCT03522649
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
Trial: NCT03522649
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
Trial: NCT04657315
Drug: MSC11FCD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration
Trial: NCT02560051
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
Trial: NCT00430170
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caffeine 4mg/kg iv
Trial: NCT01216865
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
Trial: NCT02867358
Drug: KT07 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03196557
Drug: Prenisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03196557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on dose on specified days
Trial: NCT02583048
Drug: Multidrug Background Treatment (MBT) for TB
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
Trial: NCT00148746
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02155257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00414726
Drug: NBO (Normobaric Oxygen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Trial: NCT02328040
Drug: Placebo and Insulin monotherapy via CL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
Trial: NCT02107196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
Trial: NCT00564031
Drug: Femanest
RxNorm normalized name: Femtest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/day
Trial: NCT00564031
Drug: gestapuran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/day
Trial: NCT00564031
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT00564031
Drug: Femanest plus Gestapuran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined daily
Trial: NCT03119662
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL saline, followed by a 10 mL saline flush.
Trial: NCT03362008
Drug: Champix®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of Champix®
Trial: NCT03016806
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg or 60 mg/kg
Trial: NCT00813735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily at bedtime